Hamlet Pharma secures long-term Alpha1 peptide production in an agreement with Polypeptide Group
Lund, June 12, Hamlet Pharma, ticker HAMLET, soon to be Hamlet BioPharma, the innovative pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, announces that Hamlet Pharma has extended and expanded the agreement with the Swiss public company Polypeptide Group, ticker PPGN, to produce larger quantities of the synthetic peptide Alpha1. The new production, at a larger scale, will be essential for future expansions of the clinical trial program in bladder cancer.